Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-07

AUTHORS

G. J. Peters, P. Noordhuis, A. B. P. Van Kuilenburg, J. H. Schornagel, H. Gall, S. L. Turner, M. S. Swart, D. Voorn, A. H. Van Gennip, J. Wanders, U. Holwerda, K. Smid, G. Giaccone, P. Fumoleau, C. J. Van Groeningen

ABSTRACT

S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition. More... »

PAGES

1-12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9

DOI

http://dx.doi.org/10.1007/s00280-003-0617-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036282560

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12739060


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxonic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "G. J.", 
        "id": "sg:person.01255301342.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noordhuis", 
        "givenName": "P.", 
        "id": "sg:person.01171546142.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171546142.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5650.6", 
          "name": [
            "Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Kuilenburg", 
        "givenName": "A. B. P.", 
        "id": "sg:person.010124200377.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010124200377.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schornagel", 
        "givenName": "J. H.", 
        "id": "sg:person.0600513472.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600513472.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gall", 
        "givenName": "H.", 
        "id": "sg:person.01023051473.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turner", 
        "givenName": "S. L.", 
        "id": "sg:person.0606744057.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606744057.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Swart", 
        "givenName": "M. S.", 
        "id": "sg:person.01256606405.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256606405.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voorn", 
        "givenName": "D.", 
        "id": "sg:person.01346612643.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346612643.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5650.6", 
          "name": [
            "Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Gennip", 
        "givenName": "A. H.", 
        "id": "sg:person.01220376041.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220376041.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NDDO Oncology, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wanders", 
        "givenName": "J.", 
        "id": "sg:person.01307713100.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307713100.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holwerda", 
        "givenName": "U.", 
        "id": "sg:person.01347171204.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347171204.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smid", 
        "givenName": "K.", 
        "id": "sg:person.01232364243.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232364243.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giaccone", 
        "givenName": "G.", 
        "id": "sg:person.01304747074.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304747074.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "EORTC\u2014New Drug Development Group, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fumoleau", 
        "givenName": "P.", 
        "id": "sg:person.01101667531.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Groeningen", 
        "givenName": "C. J.", 
        "id": "sg:person.016122500204.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016122500204.87"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1054/drup.1999.0089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000143703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00058-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004034553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00371-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008444022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(94)00444-q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012048074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(01)00203-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016987868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017013439", 
          "https://doi.org/10.1007/bf00685670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017013439", 
          "https://doi.org/10.1007/bf00685670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/cnv-120000360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018308252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1970.00480260061008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024508314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.5.6.637", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025883442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508229", 
          "https://doi.org/10.1007/bf00662639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508229", 
          "https://doi.org/10.1007/bf00662639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0925-4439(02)00082-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026544769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(89)90187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027438015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(89)90187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027438015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000138581", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027697939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028328879", 
          "https://doi.org/10.1007/s002800050561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498259609046718", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029977116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-59259-725-3_5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035390634", 
          "https://doi.org/10.1007/978-1-59259-725-3_5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(87)90053-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036522081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036845106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(95)00217-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041155362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1980.156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041499966", 
          "https://doi.org/10.1038/clpt.1980.156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(93)90129-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044367856"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(96)00429-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074255186", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074515759", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074570373", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.14.2772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074667570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074733629", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074797879", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3727/096504001108747729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074838513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.22.4267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074954342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076942345", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079562315", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079597830", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079977592", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080114929", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081600900", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082466563", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1994.12.10.2035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082570398"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082895728", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.1.301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083201650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.4.1450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083246640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083251777", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083320099", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083370636", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-07", 
    "datePublishedReg": "2003-07-01", 
    "description": "S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-003-0617-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "52"
      }
    ], 
    "name": "Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors", 
    "pagination": "1-12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "acd5d5a931367e586fac1b0057274724d5a4c95028c01520f1b3c8ad66ba43ff"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12739060"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-003-0617-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036282560"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-003-0617-9", 
      "https://app.dimensions.ai/details/publication/pub.1036282560"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-003-0617-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'


 

This table displays all metadata directly associated to this object as RDF triples.

382 TRIPLES      21 PREDICATES      94 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-003-0617-9 schema:about N2f8cc255dae54b96a30cde50843341c0
2 N3ffb96f3db284a02858c6c225b034019
3 N58f6f295e19c44de8175deaae53c98ab
4 N5b5b9cfa7f6d44e899c5fc7f1ed21042
5 N5d259e128d2444388f21298dd9e245c9
6 N8674c6deed014ffc8920f563ee2226e5
7 N9aad5616a51f4f45b934f882b398e4ca
8 N9ef8b08e258244388b29b6d95db4a9fa
9 Na463d9cce8cb49ceb2018d0cee1e96d2
10 Na4816663d06147a0a2b31a5a75291da5
11 Na5982655c65347718044cc4f9341ab51
12 Nb4cd5ce4ce56497bbda32354e4e593fa
13 Nb5d26b17c84c435db2a5abef2a870a6e
14 Nbbacc07431b94aff85017bfd0b3dd8f7
15 Nc6297a9a508c439bb3b09f9f68582c1f
16 Ncd62f5124cf24d8e8002b3e18397441b
17 Ne5076b99ca3141f4ab0baf3083fbcfc6
18 Neb21cde159fc4fa9a790d6dfd93577f9
19 Nf1788d46808f46b590b8087afe166355
20 Nf7da96ac397f4478820b9bd4baa3676b
21 anzsrc-for:11
22 anzsrc-for:1115
23 schema:author N2f12f7b3d2fc4391a8228abd93302ad2
24 schema:citation sg:pub.10.1007/978-1-59259-725-3_5
25 sg:pub.10.1007/bf00662639
26 sg:pub.10.1007/bf00685670
27 sg:pub.10.1007/s002800050561
28 sg:pub.10.1038/clpt.1980.156
29 https://app.dimensions.ai/details/publication/pub.1074255186
30 https://app.dimensions.ai/details/publication/pub.1074515759
31 https://app.dimensions.ai/details/publication/pub.1074570373
32 https://app.dimensions.ai/details/publication/pub.1074733629
33 https://app.dimensions.ai/details/publication/pub.1074797879
34 https://app.dimensions.ai/details/publication/pub.1076942345
35 https://app.dimensions.ai/details/publication/pub.1079562315
36 https://app.dimensions.ai/details/publication/pub.1079597830
37 https://app.dimensions.ai/details/publication/pub.1079977592
38 https://app.dimensions.ai/details/publication/pub.1080114929
39 https://app.dimensions.ai/details/publication/pub.1081600900
40 https://app.dimensions.ai/details/publication/pub.1082466563
41 https://app.dimensions.ai/details/publication/pub.1082895728
42 https://app.dimensions.ai/details/publication/pub.1083251777
43 https://app.dimensions.ai/details/publication/pub.1083320099
44 https://app.dimensions.ai/details/publication/pub.1083370636
45 https://doi.org/10.1001/archneur.1970.00480260061008
46 https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9
47 https://doi.org/10.1016/0006-2952(89)90187-1
48 https://doi.org/10.1016/0006-2952(94)00444-q
49 https://doi.org/10.1016/0277-5379(87)90053-8
50 https://doi.org/10.1016/0959-8049(93)90129-4
51 https://doi.org/10.1016/0959-8049(95)00217-7
52 https://doi.org/10.1016/s0378-4347(01)00203-1
53 https://doi.org/10.1016/s0378-4347(96)00429-x
54 https://doi.org/10.1016/s0925-4439(02)00082-0
55 https://doi.org/10.1016/s0959-8049(01)00371-9
56 https://doi.org/10.1016/s0959-8049(98)00058-6
57 https://doi.org/10.1054/drup.1999.0089
58 https://doi.org/10.1081/cnv-120000360
59 https://doi.org/10.1159/000138581
60 https://doi.org/10.1200/jco.1994.12.10.2035
61 https://doi.org/10.1200/jco.1998.16.1.301
62 https://doi.org/10.1200/jco.1998.16.4.1450
63 https://doi.org/10.1200/jco.1999.17.8.2439
64 https://doi.org/10.1200/jco.2000.18.14.2772
65 https://doi.org/10.1200/jco.2001.19.22.4267
66 https://doi.org/10.1517/13543784.5.6.637
67 https://doi.org/10.3109/00498259609046718
68 https://doi.org/10.3727/096504001108747729
69 schema:datePublished 2003-07
70 schema:datePublishedReg 2003-07-01
71 schema:description S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition.
72 schema:genre research_article
73 schema:inLanguage en
74 schema:isAccessibleForFree false
75 schema:isPartOf N679e8918f5b3497dae93d852157c6f94
76 N7dd6b21547c243e98c8c44c6d6aa2435
77 sg:journal.1088364
78 schema:name Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
79 schema:pagination 1-12
80 schema:productId N13d6087cd63c48028faac698d8e07982
81 N4fff0c3e97554497824e3b7245df09ef
82 Nb043a0fcc806469cb41364a408c62a99
83 Neae653f94c7d49838d5eac7c640ac535
84 Nf978479416314707818f602a5279a064
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036282560
86 https://doi.org/10.1007/s00280-003-0617-9
87 schema:sdDatePublished 2019-04-10T18:21
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher N85dc602662bc4e008e1115e1df47b4a0
90 schema:url http://link.springer.com/10.1007%2Fs00280-003-0617-9
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N0595a11a00274789a8f22da40038be6f rdf:first sg:person.01346612643.05
95 rdf:rest N742a7533f049423698fea347c959a4fd
96 N13d6087cd63c48028faac698d8e07982 schema:name dimensions_id
97 schema:value pub.1036282560
98 rdf:type schema:PropertyValue
99 N2bc66739569147378106d6ebca65e2da rdf:first sg:person.01101667531.56
100 rdf:rest N350848870a3c4abfb852f434a360d049
101 N2f12f7b3d2fc4391a8228abd93302ad2 rdf:first sg:person.01255301342.17
102 rdf:rest Nf7d77783ec514021b2cf06e81c150f52
103 N2f8cc255dae54b96a30cde50843341c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Area Under Curve
105 rdf:type schema:DefinedTerm
106 N350848870a3c4abfb852f434a360d049 rdf:first sg:person.016122500204.87
107 rdf:rest rdf:nil
108 N3ffb96f3db284a02858c6c225b034019 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Pyridines
110 rdf:type schema:DefinedTerm
111 N4fff0c3e97554497824e3b7245df09ef schema:name doi
112 schema:value 10.1007/s00280-003-0617-9
113 rdf:type schema:PropertyValue
114 N58f6f295e19c44de8175deaae53c98ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Female
116 rdf:type schema:DefinedTerm
117 N5b5b9cfa7f6d44e899c5fc7f1ed21042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Uracil
119 rdf:type schema:DefinedTerm
120 N5d259e128d2444388f21298dd9e245c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Neoplasms
122 rdf:type schema:DefinedTerm
123 N679e8918f5b3497dae93d852157c6f94 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 N6ae733ee4723450989ed292db1b1c0d9 rdf:first sg:person.01023051473.48
126 rdf:rest Nb647be40277c4001b1c780a295cbaf34
127 N7141c47b8f6e42b1be1f09a714b031a2 rdf:first sg:person.01347171204.78
128 rdf:rest Ncddd03b9d40847dba61c0c4c5e1cf56b
129 N742a7533f049423698fea347c959a4fd rdf:first sg:person.01220376041.48
130 rdf:rest Nccb7cd2f83de479796a75f10e61ff473
131 N7cd7c148bc0c48d98b49d284c2bfd0ad rdf:first sg:person.0600513472.36
132 rdf:rest N6ae733ee4723450989ed292db1b1c0d9
133 N7dd6b21547c243e98c8c44c6d6aa2435 schema:volumeNumber 52
134 rdf:type schema:PublicationVolume
135 N85dc602662bc4e008e1115e1df47b4a0 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 N8674c6deed014ffc8920f563ee2226e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Metabolic Clearance Rate
139 rdf:type schema:DefinedTerm
140 N923eaff9a5d842cda748559c8783d378 rdf:first sg:person.010124200377.90
141 rdf:rest N7cd7c148bc0c48d98b49d284c2bfd0ad
142 N94b1263989ff4e268f308f6287791517 schema:name EORTC—New Drug Development Group, Nantes, France
143 rdf:type schema:Organization
144 N9aad5616a51f4f45b934f882b398e4ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N9ef8b08e258244388b29b6d95db4a9fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Aged
149 rdf:type schema:DefinedTerm
150 Na463d9cce8cb49ceb2018d0cee1e96d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Oxonic Acid
152 rdf:type schema:DefinedTerm
153 Na4816663d06147a0a2b31a5a75291da5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Middle Aged
155 rdf:type schema:DefinedTerm
156 Na5982655c65347718044cc4f9341ab51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Tissue Distribution
158 rdf:type schema:DefinedTerm
159 Nb043a0fcc806469cb41364a408c62a99 schema:name nlm_unique_id
160 schema:value 7806519
161 rdf:type schema:PropertyValue
162 Nb4cd5ce4ce56497bbda32354e4e593fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Adult
164 rdf:type schema:DefinedTerm
165 Nb5d26b17c84c435db2a5abef2a870a6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Half-Life
167 rdf:type schema:DefinedTerm
168 Nb647be40277c4001b1c780a295cbaf34 rdf:first sg:person.0606744057.67
169 rdf:rest Nb9402d4c6b704aff8c1978c625d191b8
170 Nb9402d4c6b704aff8c1978c625d191b8 rdf:first sg:person.01256606405.17
171 rdf:rest N0595a11a00274789a8f22da40038be6f
172 Nbbacc07431b94aff85017bfd0b3dd8f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Dose-Response Relationship, Drug
174 rdf:type schema:DefinedTerm
175 Nc6297a9a508c439bb3b09f9f68582c1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Drug Combinations
177 rdf:type schema:DefinedTerm
178 Nccb7cd2f83de479796a75f10e61ff473 rdf:first sg:person.01307713100.00
179 rdf:rest N7141c47b8f6e42b1be1f09a714b031a2
180 Ncd62f5124cf24d8e8002b3e18397441b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antimetabolites, Antineoplastic
182 rdf:type schema:DefinedTerm
183 Ncddd03b9d40847dba61c0c4c5e1cf56b rdf:first sg:person.01232364243.35
184 rdf:rest Nee9cc2ec1acf40d0916ce585ee8b81d7
185 Ne5076b99ca3141f4ab0baf3083fbcfc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Tegafur
187 rdf:type schema:DefinedTerm
188 Ne59dcc0dafee45e2abe617a28433563c schema:name NDDO Oncology, Amsterdam, The Netherlands
189 rdf:type schema:Organization
190 Neae653f94c7d49838d5eac7c640ac535 schema:name readcube_id
191 schema:value acd5d5a931367e586fac1b0057274724d5a4c95028c01520f1b3c8ad66ba43ff
192 rdf:type schema:PropertyValue
193 Neb21cde159fc4fa9a790d6dfd93577f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Biological Availability
195 rdf:type schema:DefinedTerm
196 Nee9cc2ec1acf40d0916ce585ee8b81d7 rdf:first sg:person.01304747074.35
197 rdf:rest N2bc66739569147378106d6ebca65e2da
198 Nf1788d46808f46b590b8087afe166355 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Fluorouracil
200 rdf:type schema:DefinedTerm
201 Nf7d77783ec514021b2cf06e81c150f52 rdf:first sg:person.01171546142.92
202 rdf:rest N923eaff9a5d842cda748559c8783d378
203 Nf7da96ac397f4478820b9bd4baa3676b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Male
205 rdf:type schema:DefinedTerm
206 Nf978479416314707818f602a5279a064 schema:name pubmed_id
207 schema:value 12739060
208 rdf:type schema:PropertyValue
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
213 schema:name Pharmacology and Pharmaceutical Sciences
214 rdf:type schema:DefinedTerm
215 sg:journal.1088364 schema:issn 0344-5704
216 1432-0843
217 schema:name Cancer Chemotherapy and Pharmacology
218 rdf:type schema:Periodical
219 sg:person.010124200377.90 schema:affiliation https://www.grid.ac/institutes/grid.5650.6
220 schema:familyName Van Kuilenburg
221 schema:givenName A. B. P.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010124200377.90
223 rdf:type schema:Person
224 sg:person.01023051473.48 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
225 schema:familyName Gall
226 schema:givenName H.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48
228 rdf:type schema:Person
229 sg:person.01101667531.56 schema:affiliation N94b1263989ff4e268f308f6287791517
230 schema:familyName Fumoleau
231 schema:givenName P.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56
233 rdf:type schema:Person
234 sg:person.01171546142.92 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
235 schema:familyName Noordhuis
236 schema:givenName P.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171546142.92
238 rdf:type schema:Person
239 sg:person.01220376041.48 schema:affiliation https://www.grid.ac/institutes/grid.5650.6
240 schema:familyName Van Gennip
241 schema:givenName A. H.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220376041.48
243 rdf:type schema:Person
244 sg:person.01232364243.35 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
245 schema:familyName Smid
246 schema:givenName K.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232364243.35
248 rdf:type schema:Person
249 sg:person.01255301342.17 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
250 schema:familyName Peters
251 schema:givenName G. J.
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17
253 rdf:type schema:Person
254 sg:person.01256606405.17 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
255 schema:familyName Swart
256 schema:givenName M. S.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256606405.17
258 rdf:type schema:Person
259 sg:person.01304747074.35 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
260 schema:familyName Giaccone
261 schema:givenName G.
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304747074.35
263 rdf:type schema:Person
264 sg:person.01307713100.00 schema:affiliation Ne59dcc0dafee45e2abe617a28433563c
265 schema:familyName Wanders
266 schema:givenName J.
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307713100.00
268 rdf:type schema:Person
269 sg:person.01346612643.05 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
270 schema:familyName Voorn
271 schema:givenName D.
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346612643.05
273 rdf:type schema:Person
274 sg:person.01347171204.78 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
275 schema:familyName Holwerda
276 schema:givenName U.
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347171204.78
278 rdf:type schema:Person
279 sg:person.016122500204.87 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
280 schema:familyName Van Groeningen
281 schema:givenName C. J.
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016122500204.87
283 rdf:type schema:Person
284 sg:person.0600513472.36 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
285 schema:familyName Schornagel
286 schema:givenName J. H.
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600513472.36
288 rdf:type schema:Person
289 sg:person.0606744057.67 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
290 schema:familyName Turner
291 schema:givenName S. L.
292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606744057.67
293 rdf:type schema:Person
294 sg:pub.10.1007/978-1-59259-725-3_5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035390634
295 https://doi.org/10.1007/978-1-59259-725-3_5
296 rdf:type schema:CreativeWork
297 sg:pub.10.1007/bf00662639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026508229
298 https://doi.org/10.1007/bf00662639
299 rdf:type schema:CreativeWork
300 sg:pub.10.1007/bf00685670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017013439
301 https://doi.org/10.1007/bf00685670
302 rdf:type schema:CreativeWork
303 sg:pub.10.1007/s002800050561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028328879
304 https://doi.org/10.1007/s002800050561
305 rdf:type schema:CreativeWork
306 sg:pub.10.1038/clpt.1980.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041499966
307 https://doi.org/10.1038/clpt.1980.156
308 rdf:type schema:CreativeWork
309 https://app.dimensions.ai/details/publication/pub.1074255186 schema:CreativeWork
310 https://app.dimensions.ai/details/publication/pub.1074515759 schema:CreativeWork
311 https://app.dimensions.ai/details/publication/pub.1074570373 schema:CreativeWork
312 https://app.dimensions.ai/details/publication/pub.1074733629 schema:CreativeWork
313 https://app.dimensions.ai/details/publication/pub.1074797879 schema:CreativeWork
314 https://app.dimensions.ai/details/publication/pub.1076942345 schema:CreativeWork
315 https://app.dimensions.ai/details/publication/pub.1079562315 schema:CreativeWork
316 https://app.dimensions.ai/details/publication/pub.1079597830 schema:CreativeWork
317 https://app.dimensions.ai/details/publication/pub.1079977592 schema:CreativeWork
318 https://app.dimensions.ai/details/publication/pub.1080114929 schema:CreativeWork
319 https://app.dimensions.ai/details/publication/pub.1081600900 schema:CreativeWork
320 https://app.dimensions.ai/details/publication/pub.1082466563 schema:CreativeWork
321 https://app.dimensions.ai/details/publication/pub.1082895728 schema:CreativeWork
322 https://app.dimensions.ai/details/publication/pub.1083251777 schema:CreativeWork
323 https://app.dimensions.ai/details/publication/pub.1083320099 schema:CreativeWork
324 https://app.dimensions.ai/details/publication/pub.1083370636 schema:CreativeWork
325 https://doi.org/10.1001/archneur.1970.00480260061008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024508314
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036845106
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1016/0006-2952(89)90187-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027438015
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1016/0006-2952(94)00444-q schema:sameAs https://app.dimensions.ai/details/publication/pub.1012048074
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1016/0277-5379(87)90053-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036522081
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1016/0959-8049(93)90129-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044367856
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1016/0959-8049(95)00217-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041155362
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1016/s0378-4347(01)00203-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016987868
340 rdf:type schema:CreativeWork
341 https://doi.org/10.1016/s0378-4347(96)00429-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046560228
342 rdf:type schema:CreativeWork
343 https://doi.org/10.1016/s0925-4439(02)00082-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026544769
344 rdf:type schema:CreativeWork
345 https://doi.org/10.1016/s0959-8049(01)00371-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008444022
346 rdf:type schema:CreativeWork
347 https://doi.org/10.1016/s0959-8049(98)00058-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004034553
348 rdf:type schema:CreativeWork
349 https://doi.org/10.1054/drup.1999.0089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000143703
350 rdf:type schema:CreativeWork
351 https://doi.org/10.1081/cnv-120000360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018308252
352 rdf:type schema:CreativeWork
353 https://doi.org/10.1159/000138581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027697939
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1200/jco.1994.12.10.2035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082570398
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1200/jco.1998.16.1.301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083201650
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1200/jco.1998.16.4.1450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083246640
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1200/jco.1999.17.8.2439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549863
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1200/jco.2000.18.14.2772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074667570
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1200/jco.2001.19.22.4267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074954342
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1517/13543784.5.6.637 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025883442
368 rdf:type schema:CreativeWork
369 https://doi.org/10.3109/00498259609046718 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029977116
370 rdf:type schema:CreativeWork
371 https://doi.org/10.3727/096504001108747729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074838513
372 rdf:type schema:CreativeWork
373 https://www.grid.ac/institutes/grid.16872.3a schema:alternateName VU University Medical Center
374 schema:name Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
375 Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
376 rdf:type schema:Organization
377 https://www.grid.ac/institutes/grid.430814.a schema:alternateName Antoni van Leeuwenhoek Hospital
378 schema:name Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands
379 rdf:type schema:Organization
380 https://www.grid.ac/institutes/grid.5650.6 schema:alternateName Academic Medical Center
381 schema:name Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands
382 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...